GlassScriptPhysician profile
Matthew D Miller
NPI 1558474122
$7,615.43
in general payments reported to CMS, 2019-2025
62 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $255 · 2021: $767 · 2022: $910 · 2023: $1,504 · 2024: $1,501 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,851 · Education: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,850.63 |
| Education | $603.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $535.76 | 2021-2025 | |
| Janssen Biotech, INC. | $473.89 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Lilly USA, LLC | $433.99 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $418.77 | 2019-2024 | Prolia |
| Daiichi Sankyo INC. | $377.76 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $355.98 | 2019-2025 | |
| Genzyme Corporation | $349.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $348.67 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| Regeneron Healthcare Solutions, INC. | $325.43 | 2021-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $287.55 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Gilead Sciences, INC. | $249.03 | 2021-2025 | Trodelvy |
| Celgene Corporation | $180.44 | 2022-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $174.96 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $174.48 | 2022-2025 | |
| Incyte Corporation | $164.36 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $161.58 | 2022-2024 | Polivy, Lunsumio, Columvi |
| Btg International INC. | $159.46 | 2024-2025 | Crofab |
| Galvanize Therapeutics, INC | $156.27 | 2023 | Aliya System |
| Inari Medical, INC. | $139.24 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Karyopharm Therapeutics INC. | $131.44 | 2021-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $110.56 | 2024-2025 | Iclusig, Ninlaro |
| Janssen Scientific Affairs, LLC | $106.93 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| Eisai INC. | $106.77 | 2021-2025 | |
| Kite Pharma, INC. | $105.63 | 2020-2023 | |
| Taiho Oncology, INC. | $101.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $86.32 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Array Biopharma INC | $84.99 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Stemline Therapeutics INC. | $77.54 | 2023-2024 | Orserdu |
| Exelixis INC. | $69.17 | 2022-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $66.40 | 2020-2022 | |
| Caris Mpi, INC. | $59.17 | 2025 | Mi Cancer Seek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.96 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $54.04 | 2024 | Xarelto |
| Jazz Pharmaceuticals INC. | $54.02 | 2024-2025 | |
| Pharmaessentia USA Corporation | $52.12 | 2023-2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $48.74 | 2025 | Monoferric |
| Sobi, INC | $47.56 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $46.93 | 2024 | Orgovyx |
| Genmab U.S., INC. | $46.36 | 2022-2025 | Tivdak |
| Aveo Pharmaceuticals, INC. | $44.98 | 2022-2023 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $44.67 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $41.31 | 2021 | |
| Puma Biotechnology, INC. | $40.74 | 2022-2024 | |
| Foundation Medicine, INC. | $40.08 | 2023 | |
| Blueprint Medicines Corporation | $37.13 | 2022-2025 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $35.27 | 2022-2023 | Tavalisse, Rezlidhia |
| Seagen INC. | $33.13 | 2022-2023 | Padcev |
| Beone Medicines USA, INC. | $31.89 | 2025 | Brukinsa |
| Astellas Pharma US INC | $31.53 | 2025 | Vyloy |
| Springworks Therapeutics, INC. | $28.92 | 2025 | Ogsiveo |
| Recordati_rare_diseases_inc. | $25.52 | 2025 | Enjaymo |
| Morphosys, US INC. | $25.30 | 2023 | Monjuvi |
| Myovant Sciences INC. | $21.97 | 2021 | |
| Coherus Oncology, INC. | $21.87 | 2025 | Udenyca |
| Tempus Ai, INC | $21.73 | 2025 | Xt Cdx |
| Emd Serono, INC. | $21.29 | 2025 | |
| Novocure INC. | $17.74 | 2025 | Optune Lua (Novottf-200t) |
| Agios Pharmaceuticals, INC. | $16.07 | 2023 | Pyrukynd |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Clovis Oncology, INC. | $13.74 | 2020 | |
| Dova Pharmaceuticals | $12.99 | 2021 | |
| G1 Therapeutics, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.